Emmis Acquisition (EMIS) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Emmis Acquisition is the larger company by market cap ($163.4 million vs $149.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | RNA |
|---|---|---|
| Share price | $10.36 | $6.92 |
| Market cap | $163.36M | $149.27M |
| 1-day change | +0.15% | -0.86% |
| YTD return | +4.07% | — |
| 1-year return | +4.39% | — |
| EPS (TTM) | — | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.38 | $16.77 |
| 52-week low | $9.92 | $6.36 |
| Distance from 52-week high | -0.24% | -58.74% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +217.92% |
| Average volume | 16.19K | 297.20K |
| Shares outstanding | 11.94M | 21.57M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
EMIS vs RNA FAQ
Which is bigger, Emmis Acquisition or Atrium Therapeutics?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $163.36M compared with $149.27M for Atrium Therapeutics (RNA).
Are Emmis Acquisition and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.